Articles By Estel Grace Masangkay

  1. Novartis' Tasigna Superior Over Glivec In Ph+ CML 12/11/2014

    Novartis reported that data from its six-year pivotal study supported the superiority of its drug Tasigna (nilotinib) over its aging treatment Glivec (imatinib) in the treatment of newly-diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

  2. Sandoz' Biosimilar A Suitable Alternative To Amgen's Neupogen 12/10/2014

    Novartis company Sandoz reported late-stage data showing that its investigational biosimilar filgrastim has comparable safety and efficacy to its reference product Neupogen (filgrastim) by rival company Amgen.

  3. NICE Set To Recommend Roche's Gazyvaro For CLL 12/9/2014

    The National Institute for Health and Care Excellence (NICE) announced that it is set to recommend Roche’s (obinutuzumab) in its preliminary guidance to the National Health Service (NHS) as treatment for certain patients with chronic lymphocytic leukemia (CLL).

  4. AstraZeneca's NDA For Iressa In EGFRm NSCLC Accepted By FDA 12/9/2014

    AstraZeneca reported that its recently submitted New Drug Application (NDA) for Iressa has been accepted by the U.S. Food and Drug Administration (FDA).

  5. Sanofi, Evotec In Exclusive Talks For Toulouse Site Transfer 12/8/2014

    German drug development company Evotec announced that it is engaged in exclusive negotiations with French drug maker Sanofi for the transfer of its Toulouse facility and research operations.

  6. Pfizer Publishes Phase 3 Data For Xalkori 12/8/2014

    Pfizer announced that it has published the results of its late-stage study for Xalkori (crizotinib) as treatment for previously untreated anaplastic lymphoma kinase (ALK) -positive advanced non-small cell lung cancer (NSCLC).

  7. Array Takes Back Rights To Binimetinib From Novartis 12/8/2014

    Array BioPharma, a biopharmaceutical firm focused on developing targeted small molecule drugs against cancer, announced that it has agreed to regain full global rights to its investigational drug binimetinib from Novartis.

  8. Janssen, MBS Link For Rheumatoid Arthritis Therapy 12/5/2014

    Drug development firm Modern Biosciences announced that it has inked an R&D partnership and global option and license agreement with Janssen for its novel bone-protective compounds for the treatment of rheumatoid arthritis (RA).

  9. Pfizer Wraps Up Baxter Vaccines Acquisition Deal 12/4/2014

    Pfizer announced it has officially completed its acquisition of Baxter’s portfolio of commercialized vaccines, which include NeisVac-C and FSME-IMMUN/TicoVac.

  10. Oxford BioTherapeutics, Menarini Begin Trial Of Antibody For AML 12/3/2014

    Oxford BioTherapeutics, a company focused on developing antibody-drug conjugates (ADCs) against cancer, and its partner Italian pharma firm Menarini Group announced that the companies have started the first-in-human trial of the lead antibody OBT357 (MEN1112) for the treatment of acute myeloid leukemia (AML).